AAQoL LS mean difference for total score was 21.0 for subscale: Life Productivity was 21.0 Psychological Health was 12.1 Life Outlook was 12.5 and Relationships was 7.3. LDX improved AIM-A multi-item domain scores versus placebo LS mean difference for Performance and Daily Functioning was 21.6 (ES, 0.93, P<.0001) Impact of Symptoms: Daily Interference was 14.9 (ES, 0.62, P<.0001) Impact of Symptoms: Bother/Concern was 13.5 (ES, 0.57, P=.0003) Relationships/Communication was 7.8 (ES, 0.31, P=.0302) Living With ADHD was 9.1 (ES, 0.79, P<.0001) and General Well-Being was 10.8 (ES, 0.70, P<.0001). Of 161 randomized (placebo, 81 LDX, 80), 159 were included in the safety population. A post hoc analysis examined the subgroup having evaluable results from both AIM-A and AAQoL.
The Adult ADHD QoL (AAQoL) was added while the study was in progress. The clinician-completed ADHD Rating Scale version IV (ADHD-RS-IV) with adult prompts and Clinical Global Impressions-Severity (CGI-S) were also employed. The primary efficacy measure was the self-reported BRIEF-A a key secondary measure was self-reported QOL on the Adult ADHD Impact Module (AIM-A).
Brown attention deficit disorder scales—adult version trial#
This report highlights QOL findings from a 10-week randomized placebo-controlled trial of LDX (30–70 mg/d) in adults (18–55 years) with ADHD and EFD (Behavior Rating Inventory of EF-Adult, Global Executive Composite ≥65).
This study examined the effects of lisdexamfetamine dimesylate (LDX) on quality of life (QOL) in adults with attention-deficit/hyperactivity disorder (ADHD) and clinically significant executive function deficits (EFD).